Britta Göbel

Title: Britta Göbel: Innovator in Pharmaceutical Compositions

Introduction

Britta Göbel is a prominent inventor based in Frankfurt am Main, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds for treating various metabolic disorders. Her work focuses on combining fibroblast growth factor 21 (FGF21) with glucagon-like peptide-1 receptor (GLP-1R) agonists to optimize therapeutic outcomes.

Latest Patents

Britta Göbel holds a patent for her invention titled "FGF21 compound / GLP-1R agonist combinations with optimized activity ratio." This patent relates to combinations, pharmaceutical compositions, and fusion molecules that include an FGF21 compound and a GLP-1R agonist. The invention aims to enhance the activity ratio of these compounds, making them effective as medicaments for treating obesity, metabolic syndrome, diabetes mellitus, and other related conditions.

Career Highlights

Britta is currently employed at Sanofi, a leading global healthcare company. Her role involves extensive research and development in the pharmaceutical sector, where she applies her expertise to create innovative solutions for complex health issues. Her dedication to advancing medical science has positioned her as a key figure in her field.

Collaborations

Britta collaborates with notable colleagues, including Mark Sommerfeld and Oliver Boscheinen. These partnerships enhance her research efforts and contribute to the successful development of her patented inventions.

Conclusion

Britta Göbel is a trailblazer in the pharmaceutical industry, recognized for her innovative work in combining FGF21 and GLP-1R agonists. Her contributions are paving the way for new treatments for metabolic disorders, showcasing the impact of her research on global health.